RLF.SW

Relief Therapeutics Holding AG is a biopharmaceutical company, based in Geneva, Switzerland, and established in 2013. The firm is dedicated to providing therapeutic solutions for patients globally, including Switzerland, the rest of Europe, and North America, who suffer from serious diseases with significant unmet medical needs. The company's strategy centers on advancing clinical-stage programs, leveraging molecules that possess an established history of human use. These programs are backed either by initial data demonstrating human activity or efficacy, or by robust scientific rationale. Its primary investigational drug is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a diverse mechanism of action, designed to address various respiratory conditions. RLF-100 is currently undergoing Phase 3 clinical trials for COVID-19-induced acute respiratory distress syndrome and moderate-to-severe COVID-19 lung injury. Additionally, it is in Phase 1 clinical trials for acute lung injury in other intensive care settings and in Phase 2 trials for pulmonary sarcoidosis. Relief Therapeutics is also advancing ACER-001, a specialized powder formulation of sodium phenylbutyrate. This compound has successfully completed Phase 3 clinical trials for urea cycle disorders and is now in Phase 1 trials for maple syrup urine disease. Furthermore, the company is developing APR-TD011, a sprayable hypotonic acid-oxidizing solution, which is currently in Phase 2 clinical trials for epidermolysis bullosa.